AC Immune SA | CIK:0001651625 | 3

  • Filed: 3/20/2018
  • Entity registrant name: AC Immune SA (CIK: 0001651625)
  • Generator: EDGARfilings PROfile
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/0000950103-18-003508-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/aciu-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001651625
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfEarningsPerShareExplanatory

    20.
    Earnings per share

      
    For the Years Ended December 31,
    		 
    in CHF thousands except for share and per share data
    		 
    2017
    		  
    2016
    		  
    2015
    		 
    Net income / (loss) attributable to owners of the Company
    		  
    (26,411
    )
    		  
    (7,096
    )
    		  
    20,270
    		 
    Earnings per share (EPS):
    		            
    Basic, income / (loss) for the period attributable to equity holders
    		  
    (0.46
    )
    		  
    (0.14
    )
    		  
    0.47
    		 
    Diluted, income / (loss) for the period attributable to equity holders
    		  
    (0.46
    )
    		  
    (0.14
    )
    		  
    0.44
    		 
    Weighted-average number of shares used to compute EPS basic
    		  
    57,084,295
    		   
    50,096,859
    		   
    43,412,250
    		 
    Weighted-average number of shares used to compute EPS fully diluted
    		  
    57,084,295
    		   
    50,096,859
    		   
    46,043,198
    		 

    For the years ended December 31, 2017, 2016 and 2015 basic and diluted earnings per share is based on the weighted average number of shares issued and outstanding. Weighted-average dilutive shares outstanding excludes  antidilutive shares to be issued that totaled 1,463,056 and 1,687,900 from the computation of diluted income (loss) per common share for the years-ended December 31, 2017 and 2016, respectively. The weighted average number of equity awards outstanding for the years ended December 31, 2017 and 2016 was 1,582,612 and 2,784,245, respectively.